Dexamethasone and bacterial meningitis in Pakistan

Area of Science:

• Pediatrics
• Infectious Diseases
• Clinical Pharmacology

Background:

• Bacterial meningitis remains a significant cause of childhood mortality and morbidity globally.
• Adjunctive therapies like corticosteroids are explored to improve outcomes.
• The efficacy of dexamethasone in developing countries for bacterial meningitis is not well-established.

Purpose of the Study:

• To evaluate the effect of dexamethasone on bacterial meningitis outcomes in children within a developing country.
• To assess the impact of dexamethasone on mortality, neurological sequelae, and hearing impairment.

Main Methods:

• A prospective, double-blind, placebo-controlled trial involving 89 children (2 months to 12 years) with bacterial meningitis.
• Patients received either dexamethasone or placebo alongside standard antimicrobial treatment (ampicillin and chloramphenicol).
• Neurological, developmental, and hearing assessments were performed at 1, 4, and 12 months post-discharge.

Main Results:

• Mortality was higher in the dexamethasone group (25%) compared to the placebo group (12%).
• Dexamethasone survivors showed similar rates of neurological sequelae (26.5% vs. 24%) and higher hearing impairment (42.3% vs. 30%) than placebo survivors.
• Late presentation and impaired consciousness were independent predictors of death.

Conclusions:

• Dexamethasone therapy provided no beneficial effect on morbidity or mortality in this cohort of seriously ill bacterial meningitis patients in a developing country.
• The use of dexamethasone as adjunctive treatment is not recommended for bacterial meningitis patients in developing countries, especially those presenting late or partially treated.